Hostname: page-component-7b7567c8c-2n9c9 Total loading time: 0 Render date: 2026-11-16T06:17:09.620Z Has data issue: false hasContentIssue false

Brain 5-HT function in obsessive-compulsive disorder

Prolactin responses to d-fenfluramine

Published online by Cambridge University Press:  03 January 2018

N. A. Fineberg*
Affiliation:
St Mary's Hospital, London
A. Roberts
Affiliation:
St Mary's Hospital, London
S. A. Montgomery
Affiliation:
St Mary's Hospital, London
P. J. Cowen
Affiliation:
Littlemore Hospital, Oxford
*
Dr P. J. Cowen, Research Unit, Littlemore Hospital, Oxford OX4 4XN
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.
Background

Drugs that potentiate brain serotonin (5-HT) neurotransmission are effective in the treatment of obsessive–compulsive disorder (OCD), but it is unclear whether disturbances in brain 5-HT function play a role in the pathophysiology of OCD.

Method

We studied the prolactin response to the selective 5-HT releasing agent d-fenfluramine in 14 non-depressed, drug-free OCD patients, and 14 healthy controls matched for age and gender.

Results

The prolactin response to d-fenfluramine was significantly increased in OCD patients compared with controls.

Conclusions

The disparate results of studies of 5-HT neuroendocrine function in OCD make it unlikely that disturbances of brain 5-HT function play a central role in the pathophysiology of OCD. Increased brain 5-HT neurotransmission in non-depressed OCD subjects may represent an adaptive neurobehavioural mechanism which can be amplified to therapeutic advantage by treatment with 5-HT potentiating drugs.

Information

Type
Papers
Copyright
Copyright © 1997 The Royal College of Psychiatrists 

This journal is not currently accepting new eletters.

eLetters

No eLetters have been published for this article.